Screen Shot 2017-04-27 at 4.46.56 PM.png
cells-1872666_1920.jpg
BG-RESULTS.png
dna-1811955_960_720.jpg
scotland-NEW_01.jpg
NEW_BG_02.png
Screen Shot 2017-04-27 at 4.46.56 PM.png

Myth Meets Reality


SCROLL DOWN

Myth Meets Reality


Myth

In Celtic myth, Oisín (sometimes Ossian) was the Gælic warrior-bard of the 7th century who sought the land of youth – a magical island off the western coast of Ireland.  Today Oisín Biotechnologies is working to make the myth a reality.

Reality

Oisín Biotechnologies' ground-breaking research and technology is demonstrating that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself.  We invite you to see how.

cells-1872666_1920.jpg

The Approach


The Approach


Our First Target - Senescent Cells

When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.

Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.

Oisín is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.*


* Baker, Darren J., et al. "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan." Nature 1038.16932 (2016)

BG-RESULTS.png

Great Results


Great Results


Accomplishments to Date & the Future

There are two major challenges to clearing senescent cells using our approach.

  • First is to design and create the DNA construct that recognizes that a cell has become senescent, and then destroys it.
  • Second is to safely and efficiently deliver this construct into cells throughout the body.

Both goals have been achieved in our pioneering proof of concept experiments in 2016.

We’ve first demonstrated the ability to transduce cells both in vitro (cell culture) and in vivo (in aged mice). Then we showed that p16 positive senescent cells can be killed on demand in both in vitro and in vivo environments. Now we are embarked on experiments that will show improvements in both healthspan and lifespan in model organisms from mice to primates. And then, everything changes.

dna-1811955_960_720.jpg

The Science


The Science


The Science of SENSOlytics™

Our proprietary technology gives persistently senescent cells a helping hand to “do the right thing."  By providing an exogenous apoptotic gene, which is only transiently expressed in cells that already have the p16 gene active, we can precisely induce the senescent cell to commit suicide. Oisín has shown as much as an 80% reduction in senescent cells in cell culture and significant reductions of senescent cell burden in naturally aged mice.

 

*SENSOlytics™ is an Oisín proprietary platform technology that enables precise targeting of a senescent cell based on the DNA expression of the cell, not on surface markers or other characteristics that might be shared with normal, undamaged cells.
scotland-NEW_01.jpg

The Team


The Team


Founding Investors

 
 
 

Other Investors

GARY HUDSON - CEO

Gary Hudson is co-founder and acting CEO of Oisin Biotechnologies. Mr. Hudson is also active in several non-profits focusing on age-related disease. He provided seed funding for the SENS Research Foundation which is transforming the way the world researches and treats age-related disease. He is a major donor to and serves as an advisor to the Methuselah Foundation, dedicated to extending the healthy human lifespan by advancing tissue engineering and regenerative medicine therapies.

Prior to Oisin, Mr. Hudson has worked extensively in the field of commercial space successfully starting and growing several companies. He is best known as the founder of Rotary Rocket, which built a landing test simulator for a reusable rocket that flew three successful flights in 1999. He has won several awards during his career including Laurel Award from Aviation Week and Space Technology, the Founder’s Award from the Space Frontier Foundation and was inducted into the International Space Hall of Fame in 2014 for his contributions to the field. Mr. Hudson currently is the President of the Space Studies Institute, a non-profit dedicated to commercial space flight and human space travel.

MATTHEW SCHOLZ

Matt is a co-founder of Oisín Bio and serves as President and Chairman. A serial entrepreneur with a background in computer security and immunology, Matt is also the founder and CEO of Immusoft, a biotech firm developing a breakthrough technology that will turn a patient's B cells into miniature drug factories. He’s a graduate of the University of Washington and a frequent speaker at the UW School of Business, while also serving as a mentor for the Thiel Fellowship program.

DR. JOHN LEWIS - CHIEF SCIENCE OFFICER

Dr. John Lewis the co-founder of Oisin Oncology and heads its cancer-fighting platform technology development and clinical research. Dr. Lewis also holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta. He is an Associate Professor in the Department of Oncology and chairs the Alberta Prostate Cancer Research Initiative. Dr. Lewis has also founded three Canadian biotechnology companies.

Dr. John Lewis’s research interests lie in the areas of nanotechnology and imaging as they relate to the development of novel treatments for chronic diseases such as aging and cancer. Because no man dies of prostate cancer that stays in his prostate, the group is studying the spread, or metastasis, of cancer using advanced live imaging techniques. The group has used this approach to identify key drivers of metastatic cancer progression, and is leveraging this information to develop novel nanoparticles to block the spread of prostate and other cancers. Dr. Lewis is also the founder of several startups focused in the areas of LNP production.

STEPHEN HILBERT

Mr. Hilbert heads up corporate development for Oisin Biotechnologies. He has served as a business advisor to Oisin since its inception and has served on several biotechnology company advisory boards, specializing in business strategy and capital formation. Prior to Oisin, Mr. Hilbert’s career spans over 15 years in the banking business where he served as trusted advisor to accredited investors around the globe. Most recently he headed up a specialty alternative investment for a company in San Diego, focusing in tax and insurance strategies for family offices and investment advisors.

Mr. Hilbert is the founder of several ventures in the areas of real estate small manufacturing of novelty gifts and strategic consulting. He serves on the Overlake Hospital’s Pulse Board, assists with Children’s Hospital Guild and is the incoming Chairman at the Columbia Tower Club, a member’s club in Seattle.

NEW_BG_02.png

Contact us


Contact us


Corporate Headquarters: 

800 5th Avenue, Suite 4100, Seattle, WA 98004

 

Please complete the form below to receive more Information

Name *
Name